Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.

Authors :: Zandee, Wouter T
Brabander, Tessa
Blažević, Anela
Kam, Boen L R
Teunissen, Jaap J M
Feelders, Richard A
Hofland, Johannes
de Herder, Wouter W
Source :: The Journal of Clinical Endocrinology & Metabolism; April 2019, Vol. 104 Issue: 4 p1336-1344, 9p
Publication Year :: 2019
Abstract: Peptide receptor radionuclide therapy (PRRT) with the radiolabeled somatostatin analogue [Lutetium-177-DOTA0-Tyr3]octreotate (177Lu-DOTATATE) is widely applied for inoperable metastatic small intestinal and nonfunctioning pancreatic neuroendocrine tumors (pNETs). The aim of this study is to describe the safety and efficacy of the treatment of functioning pNETs.

Full Text Access

Tools